Ophthalmologic disorders

Teams

Imagine's Offers

The database may not be exhaustive, please do not hesitate to contact us !
  • Leber Congenital Amaurosis (LCA)
    Genotype Phenotype
    • Cohorts

      > 700 patients

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

      Fibroblasts from LCA10 patients

    Targets
    • In vivo models

      Cep290 mouse models

    • Specific targets

      CEP290, CRB1, RPGRIP1, GUCY2D, RPE65, RDH12, etc.

    Therapeutics
    • Patents

      Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof WO/2015/004133 


      Second patent (please, contact us)

    • Protocols/Technics

      Injection of naked 2'-O-Methyl-phosphorothioate (2'OMePS) antisense-oligonucleotides (AON) for LCA10 patients

    • Specific therapeutic approaches

      Antisense oligonucleotide therapy technology

       

    Clinical trials
    Stargardt disease
    Genotype Phenotype
    • Cohorts

      300 patients

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

      Fibroblasts

    Targets
    • In vitro models

      Urine-derived Renal Epithelial Cells (UREC)

    • Specific targets

      ABCA4

    Therapeutics
    • Patents

      Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof WO/2015/004133 


      Second patent (please, contact us)

    • Protocols/Technics

      Injection of naked 2'-O-Methyl-phosphorothioate (2'OMePS) antisense-oligonucleotides (AON) for LCA10 patients

    • Specific therapeutic approaches

      Antisense oligonucleotide therapy technology

    Clinical trials
    X-linked retinitis pigmentosa (XLRP)
    Genotype Phenotype
    • Cohorts

      300 patients

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

       

    Targets
    Therapeutics
    Clinical trials
  • ALDH1A3 deficiency
    Genotype Phenotype
    • Cohorts

      Please, contact us

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

    Targets
    Therapeutics
    Clinical trials
    13q32.1 deletion syndrome congenital microcoria (MCOR)
    Genotype Phenotype
    • Cohorts

      Please, contact us

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

    Targets
    • In vivo models

      MCOR deletion mouse model (35k)

    Therapeutics
    Clinical trials
    Gillepsie syndrome
    Genotype Phenotype
    • Cohorts

      Please, contact us

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

    Targets
    Therapeutics
    Clinical trials
  • Leber HON (LHON)
    Genotype Phenotype
    • Cohorts

      Please, contact us

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

    Targets
    Therapeutics
    Clinical trials
    Autosomal Dominant ON (ADONs)
    Genotype Phenotype
    • Cohorts

      Please, contact us

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

      Fibroblasts

    Targets
    • In vivo models

      Dnmt1l +/- mouse model

    • Specific targets

      DNMT1L

    Therapeutics
    Clinical trials
    Autosomal recessive ON (ARONs)
    Genotype Phenotype
    • Cohorts

      Please, contact us

    • TNGS / WES / WGS*

      "Inherited Retinal Dystrophies" gene panel (212 genes)

    • Patient samples

      DNA

    Targets
    Therapeutics
    Clinical trials

Contacts

  • Marion Pilorge

    Marion Pilorge

    Business development manager

    • marion.pilorge@institutimagine.org
    • +33 1 42 75 45 65

Our founding members

Our campuses

Our labels